Literature DB >> 28875398

Total Hilar En Bloc Resection with Left Hemihepatectomy and Caudate Lobectomy: a Novel Approach for Treatment of Left-Sided Perihilar Cholangiocarcinoma (with Video).

Cai De Lu1, Jing Huang2, Sheng Dong Wu2, Yong Fei Hua2, Ammar A Javed3, Jiong Zhe Fang2, Chun Nian Wang4, Sheng Ye2.   

Abstract

BACKGROUND: "Hilar en bloc resection" using a no-touch technique has been advocated as a standard procedure in right-sided hepatectomies for treatment of perihilar cholangiocarcinoma (PHC). In principle, it has never been reported for left-sided tumors. The aim is to describe the procedures of total hilar en bloc resection with left hemihepatectomy and caudate lobectomy (THER-LH) for advanced PHC and discuss feasibility and clinical significance of this novel technique.
METHODS: A retrospective study using a prospectively maintained database was performed to identify eight patients who had received THER-LH for advanced PHC from January 2013 to December 2015. The clinicopathological features, surgical procedures, and outcomes of these patients form the basis this study.
RESULTS: The operative time was 546 ± 158 (380-870) min, and estimated blood loss was 875 ± 690 (400-2500) ml. Time of vessel resection and reconstruction was 25.6 ± 12.3 min for the portal vein and 19.1 ± 4.9 min for the hepatic artery. Time of hilum clamping was 27.3 ± 11.9 (15-41) min. Two patients had Clavien-Dindo grade II and IVa complications of bile leakage with one developing intraabdominal abscess and bleeding. There was no perioperative mortality. Histopathologic examination revealed that all of eight patients had tubular adenocarcinoma with microscopic invasion to the resected hepatic arteries and portal veins in seven patients. Negative bile duct margins were achieved in all of them. Three patients developed recurrence and died at 11, 18, and 24 months postoperatively. The remaining patients were alive at the time of last follow-up. The median survival was 24 months with one patient achieving a disease-free survival of 50 months.
CONCLUSION: THER-LH is a technically demanding procedure that is safe and feasible that may have some beneficial effects on the prognosis of these patients with advanced PHC. Further studies are required to confirm the oncological superiority and survival benefits of this novel technique.

Entities:  

Keywords:  Hilar en block resection; Left hemihepatectomy; Perihilar cholangiocarcinoma

Mesh:

Year:  2017        PMID: 28875398     DOI: 10.1007/s11605-017-3561-4

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  23 in total

1.  Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma--a single center experience.

Authors:  M F Gerhards; T M van Gulik; L T de Wit; H Obertop; D J Gouma
Journal:  Surgery       Date:  2000-04       Impact factor: 3.982

2.  Liver hanging maneuver: a safe approach to right hepatectomy without liver mobilization.

Authors:  J Belghiti; O A Guevara; R Noun; P F Saldinger; R Kianmanesh
Journal:  J Am Coll Surg       Date:  2001-07       Impact factor: 6.113

3.  Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not?

Authors:  Masaru Miyazaki; Atsushi Kato; Hiroshi Ito; Fumio Kimura; Hiroaki Shimizu; Masayuki Ohtsuka; Hiroyuki Yoshidome; Hideyuki Yoshitomi; Katsunori Furukawa; Satoshi Nozawa
Journal:  Surgery       Date:  2007-03-23       Impact factor: 3.982

4.  Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma.

Authors:  Peter Neuhaus; Armin Thelen; Sven Jonas; Gero Puhl; Timm Denecke; Wilfried Veltzke-Schlieker; Daniel Seehofer
Journal:  Ann Surg Oncol       Date:  2011-10-01       Impact factor: 5.344

5.  Operative outcome and problems of right hepatic lobectomy with pancreatoduodenectomy for advanced carcinoma of the biliary tract.

Authors:  Takehiro Ota; Tatuo Araida; Masakazu Yamamoto; Ken Takasaki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2007-03-27

6.  A comparative study of postoperative complications after hepatectomy in patients with and without chronic liver disease.

Authors:  Y Midorikawa; K Kubota; T Takayama; H Toyoda; M Ijichi; G Torzilli; M Mori; M Makuuchi
Journal:  Surgery       Date:  1999-09       Impact factor: 3.982

7.  Selective hepatic vascular exclusion versus Pringle maneuver in major liver resections: prospective study.

Authors:  Vassilios E Smyrniotis; Georgia G Kostopanagiotou; John C Contis; Charalampos I Farantos; Dionisios C Voros; Dimitrios C Kannas; John S Koskinas
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

8.  Surgery for hilar cholangiocarcinoma: the Leeds experience.

Authors:  E Hidalgo; S Asthana; H Nishio; J Wyatt; G J Toogood; K R Prasad; J P A Lodge
Journal:  Eur J Surg Oncol       Date:  2007-11-26       Impact factor: 4.424

9.  Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience.

Authors:  Manousos M Konstadoulakis; Sasan Roayaie; Ilias P Gomatos; Daniel Labow; Maria-Isabell Fiel; Charles M Miller; Myron E Schwartz
Journal:  Am J Surg       Date:  2008-05-07       Impact factor: 2.565

10.  No-touch resection of hilar malignancies with right hepatectomy and routine portal reconstruction.

Authors:  Satoshi Hirano; Satoshi Kondo; Eiichi Tanaka; Toshiaki Shichinohe; Takahiro Tsuchikawa; Kentaro Kato
Journal:  J Hepatobiliary Pancreat Surg       Date:  2009-04-10
View more
  2 in total

1.  Transhepatic Direct Approach to the "Limit of the Division of the Hepatic Ducts" Leads to a High R0 Resection Rate in Perihilar Cholangiocarcinoma.

Authors:  Takehiro Noji; Kimitaka Tanaka; Aya Matsui; Yoshitsugu Nakanishi; Toshimichi Asano; Toru Nakamura; Takahiro Tsuchikawa; Keisuke Okamura; Satoshi Hirano
Journal:  J Gastrointest Surg       Date:  2021-01-05       Impact factor: 3.452

2.  Effect of hepatic artery resection and reconstruction on the prognosis of patients with advanced hilar cholangiocarcinoma.

Authors:  Yuan-Ming Li; Zhi-Xin Bie; Run-Qi Guo; Bin Li; Cheng-En Wang; Fei Yan
Journal:  World J Gastrointest Oncol       Date:  2022-04-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.